Atypical fibroxanthoma is a rare, low-grade superficial sarcoma that frequently presents as a red nodule or plaque. It is considered a superficial variant of undifferentiated pleomorphic sarcoma (formerly known as malignant fibrous histiocytoma). Although atypical fibroxanthoma has similar histologic features to undifferentiated pleomorphic sarcoma, it behaves less aggressively.
Earn CME credit as you help guide your clinical decisions.
The etiology of atypical fibroxanthomas is poorly understood. Researchers believe it arises from myofibroblasts or fibroblast-like cells. Ultraviolet light apppears to play a significant role since most lesions appear on the sun-exposed head and neck of White race patients. Genetic factors also contribute to the development of atypical fibroxanthoma, since it shares genetic alterations with undifferentiated pleomorphic sarcomas, including chromosome 9p and 13q deletions. However, undifferentiated pleomorphic sarcoma has a statistically significant larger amount of genomic alterations and a more aggressive clinical course. Other possible risk factors for atypical fibroxanthoma include trauma to the skin, radiation therapy, and immunosuppression (e.g., diabetes, HIV, organ transplant).
Atypical fibroxanthomas most commonly are seen on the head and neck of elderly White race patients. Other reported sites of atypical fibroxanthoma include the trunk, shoulders, upper extremities, and dorsum of the hands. Trunk and limb lesions appear to occur more commonly in younger patients (mean age 39) compared to head and neck lesions in the elderly (mean age 69). A review of 171 cases in Western Australia found a patient age-range of 41 to 97 years old (median age 74), with 76% of the tumors occurring in men. Atypical fibroxanthoma also has been reported in patients as young as 13 with predisposing disorders such as Li-Fraumeni syndrome and xeroderma pigmentosum. The incidence increases in immunosuppressed populations, with an estimated incidence of 78 per 100,000 transplant patients.
The pathophysiology of atypical fibroxanthomas is poorly characterized. Ultra-violet (UV) light has implications for its pathogenesis due to atypical fibroxanthoma predilection for sun-exposed areas of the body and the presence of atypical fibroxanthoma in xeroderma pigmentosum patients who exhibit defective repair of UV-induced cyclobutane pyrimidine dimers. Research has documented these UV-induced pyrimidine dimers have in atypical fibroxanthoma lesions, along with mutations in the tumor suppressor gene p53. A variety of rare genetic disorders have correlations with p53-induced atypical fibroxanthomas, including Li-Fraumeni syndrome (with germline p53 mutations) and xeroderma pigmentosum. One study showed that mutations of H-Ras and K-Ras genes were present in malignant fibrous histiocytoma but not in atypical fibroxanthoma lesions; this research may prove helpful in establishing the diagnosis of atypical fibroxanthoma.
Hematoxylin and eosin stains of atypical fibroxanthoma lesions show a dermally-based tumor with pleomorphism, atypical mitotic figures, and a spindly architecture. Atypical fibroxanthoma lesions occasionally extend to the subcutaneous tissue. Note that atypical fibroxanthoma is a dermal-based process, while spindle cell squamous cell carcinoma variants (on the differential diagnosis) connect with the epidermis and show signs of keratinization. Multinucleated giant cells and solar elastosis are often present in atypical fibroxanthoma biopsy specimens, while a mixed inflammatory infiltrate may be found at the edge of the tumor. Immunohistochemistry is required to rule out other neoplasms, including spindloid squamous cell carcinoma, melanoma, and undifferentiated pleomorphic sarcoma.
Since atypical fibroxanthoma stains positive for several non-specific stains, including CD10, p53, S100A6, vimentin, and procollagen-1, it is considered a diagnosis of exclusion histologically. Of note, atypical fibroxanthoma stains negative for HMB-45, p40 (often positive in squamous cell carcinoma), desmin, pan-cytokeratin stains, CD31, and has sparse staining for S100, which may help differentiate it from melanoma. Since poorly differentiated sarcomatoid carcinomas may lose cytokeratin expression, a variety of cytokeratin stains should be used. Severe variants of atypical fibroxanthoma have been described based on various histologic findings, including pigmented atypical fibroxanthoma due to hemosiderin deposit and not actual melanin pigment, granular cell atypical fibroxanthoma, sclerotic atypical fibroxanthoma, spindle cell nonpleomorphic atypical fibroxanthoma, osteoid atypical fibroxanthoma, chondroid atypical fibroxanthoma, myxoid atypical fibroxanthoma, keloidal atypical fibroxanthoma, osteoclast-like giant-cell rich atypical fibroxanthoma, and clear cell atypical fibroxanthoma.
While there is no direct association to date, researchers hypothesize that arsenic exposure may predispose patients to atypical fibroxanthoma.
History and Physical
Atypical fibroxanthomas present as well-circumscribed red or pink nodules or plaque that may have ulceration, crust, or scale. Atypical fibroxanthoma lesions are typically small in size, with a median diameter of 1 cm, with less than 5% of the lesions being greater than 2 cm in diameter. They often develop rapidly but lack symptoms such as pain or pruritus. More than 90% of atypical fibroxanthoma tumors occur on the head and neck, while the remaining cases typically present on the extremities and trunk. Dermoscopy of lesions reveals polymorphic vessels (linear, dotted, hairpin, arborescent, and/or highly tortuous vessels) radiating to the center of the lesion with intervening white areas. The differential diagnosis includes basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, amelanotic melanoma, leiomyosarcoma, atypical (pseudosarcomatous) dermatofibroma, pleomorphic dermal sarcomas, and metastasis from internal malignancies. Compared to atypical fibroxanthoma, pleomorphic dermal sarcomas are often clinically larger and are more likely to recur locally and metastasize.
A skin biopsy is the diagnostic gold standard for atypical fibroxanthoma since it is a rare condition that clinically mimics basal and squamous cell carcinomas, Merkel cell carcinomas, and amelanotic melanomas. Immunohistochemistry is a common test performed to make the diagnosis (see "histopathology" above).
When atypical fibroxanthoma lesions have metastasized or are poorly accessible (e.g., subungual lesions), magnetic resonance imaging (MRI) may be helpful, which shows intermediate T1 and T2-weighted signal intensity compared to the high signal intensity of squamous cell carcinoma and melanoma.
Treatment / Management
Fortunately, atypical fibroxanthoma rarely metastasizes and recurs in only 6% to 10% of cases. Risk factors for metastases include immunocompromised patients, tumor depth, vascular or perineural invasion, and the presence of tumor necrosis. The most commonly reported locations for metastases include the parotid gland, lymph nodes, and subcutaneous tissue. Metastases, when present, are typically evident 12 to 24 months after the initial diagnosis of atypical fibroxanthoma. The treatment of choice for atypical fibroxanthoma is surgical excision. Previously, this utilized 1 cm margins, however Mohs micrographic surgery and regular follow-up have become the standard of care, with recurrence rates reported at 0.0% to 6.9%. In patients who are poor surgical candidates, electronic brachytherapy has successfully treated atypical fibroxanthoma and is even more effective if there is tumor debulking before therapy. Another reported treatment modality is electrodesiccation and curettage, which may be appropriate for slow-growing lesions that are less than 1 cm in diameter.
- Amelanotic melanoma
- Atypical fibroxanthoma
- Basal cell carcinoma
- Dermatofibroma with monster cell
- undifferentiated pleomorphic sarcoma
- Merkel cell carcinoma
- Pleomorphic dermal
Atypical fibroxanthoma rates a low-grade sarcoma, usually occurring on sun-exposed areas of the head and neck in elderly patients. The prognosis is generally excellent when treated with adequate excision of the primary tumor. Recurrence of the tumor occurs in approximately 5% of cases.
When promptly addressed and treated through adequate excision, atypical fibroxanthoma seldom causes any complications. It can exhibit significant sclerosis in some instances. There have also been some cases of metastatic involvement, although these are rare.
Pearls and Other Issues
Prevention of atypical fibroxanthoma is centered around UV-protection and yearly full-body skin exams for early detection.
Enhancing Healthcare Team Outcomes
Healthcare workers, including nurse practitioners, may frequently encounter skin growths in patients. Because the differential of dermal growths is large, these patients require a referral to a dermatologist or plastic surgeon for a definitive diagnosis. Atypical fibroxanthoma is one such growth that often presents in elderly persons of the White race. Risk factors for metastases include immunocompromised patients, tumor depth, vascular or perineural invasion, and the presence of tumor necrosis. The most commonly reported locations for metastases include the parotid gland, lymph nodes, and subcutaneous tissue. The treatment of choice for atypical fibroxanthoma is surgical excision. The key is to educate the patient on avoiding sun exposure and getting regular physical exams for early detection. Recurrence can occur, but metastatic spread is rare. [Level 5]
Merati M,Scott J,Honda K,Bordeaux J, Atypical Fibroxanthoma Invading Parietal Bone. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2018 Dec; [PubMed PMID: 30481164]
Klebanov N,Hoang MP,Reddy BY, Pleomorphic Dermal Sarcoma of the Scalp. Cureus. 2018 Jul 13; [PubMed PMID: 30237940]
Fix LN,Khanna T,Lewin JM, Atypical Fibroxanthoma Arising in a Burn Scar Treated With Mohs Micrographic Surgery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2018 Sep; [PubMed PMID: 30141777]
Giorgini C,Barbaccia V,Croci GA,Imarisio I,Vassallo C, Rapid development of atypical fibroxanthoma during vismodegib treatment. Clinical and experimental dermatology. 2019 Jan; [PubMed PMID: 30132948]
Tolkachjov SN,Kelley BF,Alahdab F,Erwin PJ,Brewer JD, Atypical fibroxanthoma: Systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision. Journal of the American Academy of Dermatology. 2018 Nov; [PubMed PMID: 29981390]Level 1 (high-level) evidence
Worley B,Nemechek AJ,Stoler S,Cohen JL, Naturopathic Self-Treatment of an Atypical Fibroxanthoma: Lessons for Dermatologic Surgery. Journal of drugs in dermatology : JDD. 2018 Jun 1; [PubMed PMID: 29879257]
Winchester D,Lehman J,Tello T,Chimato N,Hocker T,Kim S,Chang J,Markey J,Yom SS,Ryan W,Mully T,Hodge D,Otley C,Arron ST, Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes. Journal of the American Academy of Dermatology. 2018 Nov; [PubMed PMID: 29787841]
Moscarella E,Piana S,Specchio F,Kyrgidis A,Nazzaro G,Eliceche ML,Savoia F,Bugatti L,Filosa G,Zalaudek I,Scarfi F,Inskip M,Rosendahl C,Pyne JH,Siggs G,Toğral AK,Cabo H,Drlik L,Lallas A,Longo C,Argenziano G, Dermoscopy features of atypical fibroxanthoma: A multicenter study of the International Dermoscopy Society. The Australasian journal of dermatology. 2018 Nov; [PubMed PMID: 29569417]Level 2 (mid-level) evidence
Bitel A,Schönlebe J,Krönert C,Wollina U, Atypical fibroxanthoma: An analysis of 105 tumors. Dermatologic therapy. 2020 Jul 3; [PubMed PMID: 32618393]
Mirza B,Weedon D, Atypical fibroxanthoma: a clinicopathological study of 89 cases. The Australasian journal of dermatology. 2005 Nov; [PubMed PMID: 16197421]Level 3 (low-level) evidence
Bruecks AK,Medlicott SA,Trotter MJ, Atypical fibroxanthoma with prominent sclerosis. Journal of cutaneous pathology. 2003 May; [PubMed PMID: 12753176]
Wang WL,Torres-Cabala C,Curry JL,Ivan D,McLemore M,Tetzlaff M,Zembowicz A,Prieto VG,Lazar AJ, Metastatic atypical fibroxanthoma: a series of 11 cases including with minimal and no subcutaneous involvement. The American Journal of dermatopathology. 2015 Jun; [PubMed PMID: 25590287]Level 3 (low-level) evidence